Surprisingly, when CTLA-4 blockade was given in three dosages of 800 μg in a two-day interval – instead of the six day interval employed in our triple therapy protocol – the treatment was able to produce tumor free long-term survival. The gene discussed is CTLA4; the disease is neoplasm.